title: Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
authors.forename: Craig J
authors.initials: CJ
authors.lastname: Currie
authors.forename: Phil
authors.initials: P
authors.lastname: McEwan
authors.forename: Chris
authors.initials: C
authors.lastname: Poole
authors.forename: William J
authors.initials: WJ
authors.lastname: Valentine
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Palmer
authors.forename: Morten
authors.initials: M
authors.lastname: Lammert
authors.forename: Lars
authors.initials: L
authors.lastname: Nicklasson
authors.forename: Volker
authors.initials: V
authors.lastname: Foos
authors.forename: Stéphane
authors.initials: S
authors.lastname: Roze
mesh_terms: D061265:Biphasic Insulins; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017048:Health Care Costs; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D061267:Insulin Aspart; D000069036:Insulin Glargine; D007336:Insulin, Isophane; D049528:Insulin, Long-Acting; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D061265:Biphasic Insulins; D007328:Insulin; D049528:Insulin, Long-Acting; C557564:insulin aspart, insulin aspart protamine drug combination 30:70; D000069036:Insulin Glargine; D007336:Insulin, Isophane; D061267:Insulin Aspart